Page 235 - Read Online

Page 16 of 17 Gabriele et al. J Cancer Metastasis Treat 2018;4:17 I http://dx.doi.org/10.20517/2394-4722.2018.06

cancer cells. Carcinogenesis 2001;22:409-14.
93. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis
in prostate cencar PC3 cells. Prostate 2010;70:971-81.
94. Chhipa RR, Wu Y, Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to
androgen deprivation and hypoxia. Cell Signal 2011;23:1466-72.
95. Jiang Q, Yeh S, Wang X, Xu D, Zhang Q, Wen X, Xia S, Chang C. Targeting androgen receptor leads to suppression of prostate cancer
via induction of autophagy. J Urol 2012;188:1361-8.
96. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis, and
microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci
U S A 1998;95:10820-5.
97. Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during
energy stress. Cell Signal 2010;221554-61.
98. Meijer AJ, Codogno P. AMP-activated protein kinase and autophagy. Autophagy 2007;3:238-40.
99. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace
A, Dritschilo A, Collins SP. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther
2009;8:733-41.
100. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically
regulate the activity of Atg4. EMBO J 2007;26:1749-60.
101. Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Pinthus JH. Inter-related in vitro effects
of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int J Oncol
2010;37:761-6.
102. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal
2012;24:981-90.
103. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009;15:5308-16.
104. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-93.
105. Saleem A, Dvorzhinski D, Santanam U, Mathew R, Bray K, Stein M, White E, DiPaola RS. Effect of dual inhibition of apoptosis and
autophagy in prostate cancer. Prostate 2012;72:1374-81.
106. Nakajima Y, DelliPizzi AM, Mallouh C, Ferreri NR. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines.
Prostate 1996;29:296-302.
107. Giampietri C, Petrungaro S, Padula F, D’Alessio A, Marini ES, Facchiano A, Filippini A, Ziparo E. Autophagy modulators sensitize
prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis. Apoptosis 2012;17:1210-22.
108. He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y. Attenuation of TNFSF10/TRAIL induced apoptosis by an autophagic
survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy 2012;8:1811-21.
109. Shin S, Jing K, Jeong S, Kim N, Song KS, Heo JY, Park JH, Seo KS, Han J, Park JI, Kweon GR, Park SK, Wu T, Hwang BD, Lim K.
The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-
mTOR signaling in prostate cancer cells expressing mutant p53. Biomed Res Int 2013;2013:568671.
110. Xu AH, Hu ZM, Qu JB, Liu SM, Syed AK, Yuan HQ, Lou HX. Cyclic bisbibenzyls induce growth arrest and apoptosis of human
prostate cancer PC3 cells. Acta Pharmacol Sin 2010;31:609-15.
111. Jiang H, Sun J, Xu Q, Liu Y, Wei J, Young CY, Yuan H, Lou H. Marchantin M: a novel inhibitor of proteasome induces autophagic cell
death in prostate cancer cells. Cell Death Dis 2013;4:e761.
112. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90-100.
113. Kung HJ. Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer 2011;2:38-46.
114. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-95.
115. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434-40.
116. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. Autophagy blockade
sensitizes prostate cancer cells towards src family kinase inhibitors. Genes Cancer 2010;1:40-9.
117. Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh
CT, Evans CP, Patterson R, Lam KS, Kung HJ. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis
2014;5:e1409.
118. Qui Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosin kinase with a pleckstrin-homology domain, is an effectorof
phosphatidylinositol 3’-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl
Acad Sci U S A 1998;95:3644-9.
119. Jiang T, Guo Z, Dai B, Kang M, Ann DK, Kung HJ, Qui Y. Bi-directional regulation between tyrosine kinase Etk/BMX and tumor
suppressor p53 in response to DNA damage. J Biol Chem 2004;279:50181-9.
120. Wu YM, Huang CL, Kung HJ, Huang CY. Proteolytic activation of ETK/Bmx tyrosine kinase by caspase. J Biol Chem 2001;276:17672-8.
121. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. Interleukin-8 confers androgen-independent growth and migration
of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197-205.
122. Vallo S, Mani J, Stastny M, Makarević J, Juengel E, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA. PXD101 potentiates hormonal
therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models
of prostate cancer. Endocr Relat Cancer 2013;20:321-37.